BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Crucell N.V. 

Archimedesweg 4
P.O. Box 2048
CA Leiden    2301  The Netherlands
Phone: 31-0-71-524-8701 Fax: 31-0-71-524-8702


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology

Segment
Vaccines





 Company News
Ebola Clinical Trials: Big Name Players In The Ebola Race 10/20/2014 3:28:01 AM
Johnson & Johnson (JNJ) Jumps Into The Ebola Race With Collaboration Of Crucell (JNJ) And Bavarian Nordic (BAVA.CO); Human Trials To Start In Early 2015 9/4/2014 6:06:51 AM
Mucosis B.V. Signs Research and License Option Agreement With Crucell N.V. (CRXL) 10/8/2012 10:44:12 AM
CLC bio Delivers Specialized Antibody Engineering and Selection Software for Crucell N.V. (CRXL) 6/8/2012 9:33:51 AM
ARTES Biotechnology Announces a Strategic Collaboration Deal for Vaccine Development 4/24/2012 9:54:26 AM
Judgment Issued in Crucell N.V. (CRXL) Buy-Out Proceedings 2/28/2012 9:02:25 AM
Crucell N.V. (CRXL) Release: Promising Results of Novel Combination Vaccine 1/5/2012 11:09:37 AM
Crucell N.V. (CRXL) Discovers Important New Antibody Against Influenza A 7/8/2011 9:28:26 AM
Isconova Enters into Adjuvant License Agreement with Crucell N.V. (CRXL) 6/9/2011 9:25:39 AM
Crucell N.V. (CRXL), GlaxoSmithKline (GSK) And PATH MVI Partner to Develop Second-Generation Vaccine Against Malaria 6/7/2011 7:54:15 AM
12345678910...